Oragenics Inc. (OGEN)
AMEX AMEX Primary Summary
Oragenics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| KMT Kirk M. Tokheim Ameritas Advisory Services LLC | 2,000 | $1,120.2 | $1,240 | $119.8 | 10.69% |
Oragenics Inc. (OGEN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Oragenics Inc. ever had a stock split?
Oragenics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Janet Huffman CEO | AMEX Exchange | 684023609 CUSIP |
| US Country | 3 Employees | - Last Dividend | 28 Sep 2010 Last Split | - IPO Date |
Overview
Oragenics, Inc. is a development-stage biopharmaceutical company focused on the research and development of innovative pharmaceutical solutions, including nasal delivery medications aimed at neurology and combating infectious diseases within the United States. Initially established as Oragen, Inc., the company underwent a name change to Oragenics, Inc. following its incorporation in 1996. Operating out of its headquarters in Tampa, Florida, Oragenics, Inc. is dedicated to developing groundbreaking treatments to address unmet medical needs, leveraging advanced science and technology with a particular emphasis on neurosteroids and novel antibiotics.
Products and Services
- ONP-002
ONP-002 stands as Oragenics, Inc.'s lead product, characterized as a fully synthetic, non-naturally occurring neurosteroid. Designed to be lipophilic, ONP-002 has the capability to cross the blood-brain barrier effectively, thereby reducing swelling, oxidative stress, and inflammation. Additionally, it aims to restore proper blood flow through gene amplification, marking a significant advancement in the treatment of neurologic conditions.
- NT-CoV2-1
Oragenics, Inc. is also engaged in the development of NT-CoV2-1, a vaccine candidate poised to tackle SARS-CoV-2, the virus responsible for COVID-19. This effort illustrates the company’s commitment to contributing towards global health challenges, particularly in the realm of infectious diseases.
- Lantibiotic Product Candidate: Mutacin 1140 (MU1140)
MU1140 represents a novel class of antibiotics known as Lantibiotics, which Oragenics, Inc. is currently developing. This molecule, arising from the company's exploratory efforts, showcases potential as a new antimicrobial agent capable of combating antibiotic-resistant bacteria, highlighting the company's innovative approach in addressing critical needs in healthcare.
